After two historic approvals, Editas unveils promising early results for its sickle cell therapy: #ASH23
SAN DIEGO — As its competitors celebrate the landmark approval of two sickle cell gene therapies, Editas Medicine detailed promising early results in a small group of patients for its own gene-edited sickle cell treatment.
Across two studies in sickle cell disease and transfusion-dependent β-thalassemia, Editas reported that 11 patients have not had pain crises known as vaso-occlusive events since receiving its gene-edited therapy, known as EDIT-301. But, on average, the patients have not been followed for very long in the study — between a few weeks and one and a half years. The data were presented at the American Society of Hematology annual meeting on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
